Bristol goes pivotal with SystImmune-partnered conjugate
The first global pivotal trial will be in first-line triple-negative breast cancer.
DualityBio tries to float again
The group expects to raise nearly $170m.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
Elevation brings Synaffix on board in HER3
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.